Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma

Phase 1

Completed

• Conditions: Glioblastoma; Glioma; GBM
• Interventions: Drug: Trans Sodium Crocetinate (TSC)

• Registration Number: NCT01465347
• Lead Sponsor: Diffusion Pharmaceuticals Inc

Brief Summary

This open-label study evaluated the safety and efficacy of TSC when dosed concomitantly with the standard of care (radiation therapy and temozolomide) for newly diagnosed glioblastoma in adults. All patients received TSC in the study. The objective of the study was to evaluate the effect of TSC on survival and tumor response in patients with GBM while establishing an acceptable patient risk profile.

Detailed Description

The overall objectives of this Phase 1/2 clinical study in newly diagnosed GBM patients was to evaluate the safety and tolerability, efficacy, PK profile, PFS/time to disease progression, QoL, and overall survival in adults when TSC is added to the standard of care regimen of radiation therapy and temozolomide. All patients received TSC in this study. The primary objective of the Phase 1 portion of the study was to evaluate the safety (DLT rate) and to define the dosing regimen of TSC for the larger Phase 2 study. The primary clinical endpoint was overall survival at 24 months and patients will be followed for up to 3 years.

Study Timeline

• Study First Submitted: 2011-11-02
• Study First Submitted QC: 2011-11-02
• Study First Posted: 2011-11-04
• Study Start: 2012-02
• Primary Completion: 2015-11
• Study Completion: 2016-02
• Results First Submitted: 2016-10-04
• Status Verified: 2017-06
• Results First Submitted QC: 2017-06-16
• Last Update Submitted: 2017-06-16
• Results First Posted: 2017-07-14
• Last Update Posted: 2017-07-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 59

Inclusion Criteria

• Aged at least 18 years of age; male or female. A patient who is 70 years of age or older may be considered for enrollment after review of patient clinical and laboratory data by the Protocol Medical Monitor.
• Histologically confirmed diagnosis of GBM.
• Contrast enhancing disease on MRI within 21 days prior to screening.
• Karnofsky score (KPS) of ≥ 60 at Screening.
• No prior RT, chemotherapy (including Gliadel wafer), immunotherapy or therapy with a biologic agent, or hormonal therapy. Glucocorticoid therapy is allowed.
• Within 2 weeks of baseline visit, hematologic and renal functions as specified: Absolute neutrophil count ≥ 1500/mm3, platelets ≥ 100,000/mm3, Hgb ≥ 9.0g/dL, creatinine ≤ 1.7mg/dl, total bilirubin ≤ 1.5mg/dL, blood urea nitrogen (BUN) within 2 times the upper limit of normal, transaminases ≤ 4 times above the upper limits of the institutional norm.
• Sexually active patients must use an acceptable method of contraception while receiving doses of study medication.
• Females of childbearing potential must have a negative serum or urine pregnancy test at screening and have additional pregnancy tests during study.

Exclusion Criteria

• Patient who cannot undergo MRI.
• Pregnant or lactating.
• Serious concurrent infection or medical illness that would jeopardize the ability of the patient to receive study treatment with reasonable safety.
• Patient receiving concurrent chemotherapeutics or investigational agents within 30 days of baseline assessments, including gliadel wafers or gliasite application.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
TSC 0.25 mg/kg for 9 or 18 doses	Trans Sodium Crocetinate (TSC)	This was an open-label, sequential-cohort, dose-escalation study in two phases. Phase 1 was a safety run-in evaluating Trans Sodium Crocetinate (TSC) in 3 subjects who received 3 doses per week for 3 weeks (9 doses in total). Phase 2 engaged 56 subjects who received 3 doses per week for 6 weeks (18 doses in total). TSC was consistently dosed at 0.25mg/kg in both phases.

Primary Outcome Measures

Name	Time	Method
Dose Limiting Toxicities (DLTs)	During phase 1	Number of Participants in Phase 1 with Dose Limiting Toxicities (DLTs)
Overall Survival	6, 12, 18, 24 months	Participants in phase 2 (18 dose group, 6 weeks treatment with TSC) were monitored for up to 3 years (last follow-up - February 16, 2016). Overall Survival (OS) was defined as the length of time from the date of tumor resection surgery or definitive biopsy to the date of death. The OS analyses were performed using the Kaplan-Meier estimate method. The OS rates at 6, 12, 18 and 24 months were estimated. Median OS values were calculated; a corresponding 95% confidence interval for each median value was determined using a log rank analysis. The length of OS (in months) was calculated as follows: date of death or censored - date of surgery or definitive biopsy / 30.4375.

Secondary Outcome Measures

Name	Time	Method
Progression-Free Survival (PFS)	6,12,18, 24 months	The PFS analyses were performed using the Kaplan-Meier estimate method. The PFS rates at 6, 12, 18 and 24 months were estimated. Median PFS values were calculated; a corresponding 95% confidence interval for each median value was determined using a log rank analysis. Time to disease progression (in months) was calculated as follows: date of event\* or censoring - date of surgery or definitive biopsy / 30.4375; \*event = first tumor progression or death.
Number of Participants With Reduction in Tumor Size, According to Percentage of Tumor Reduction	From Baseline to Week 110	The sum of the product of the diameters of the tumor (using recorded tumor diameter measurements made from brain MRI images) was used to express tumor size. Results were summarized for actual and percentage change from baseline. Individual subjects results were listed, including tumor volume and tumor response from independent reviewers. Investigator data were listed but not used in the analysis. Percent response (according to independent reviewer assessments) by percentage tumor reduction from tumor resection or definitive biopsy to the last MRI were summarized.

Trial Locations

Locations (18)

USC/Norris Comprehensive Cancer Center; 🇺🇸 Los Angeles, California, United States

University of Florida McKnight Brain Institute; 🇺🇸 Gainesville, Florida, United States

Emory University Winship Cancer Institute; 🇺🇸 Atlanta, Georgia, United States

University of Kentucky Markey Cancer Center; 🇺🇸 Lexington, Kentucky, United States

Rush University Medical Center; 🇺🇸 Chicago, Illinois, United States

Forsyth Regional Cancer Center; 🇺🇸 Winston-Salem, North Carolina, United States

Penn State University Milton S. Hershey Medical Center; 🇺🇸 Hershey, Pennsylvania, United States

UVA Health Sciences Center Emily Couric Clinical Cancer Center; 🇺🇸 Charlottesville, Virginia, United States

Froedtert & Medical College of Wisconsin Cancer Center; 🇺🇸 Milwaukee, Wisconsin, United States

University of Texas Health Science Center Memorial Hermann Medical Center; 🇺🇸 Houston, Texas, United States

North Shore University Hospital; 🇺🇸 Manhasset, New York, United States

Baylor University Medical Center; 🇺🇸 Dallas, Texas, United States

St. Joseph's Medical Center Barrow Neurology Clinics; 🇺🇸 Phoenix, Arizona, United States

The George Washington University Medical Center; 🇺🇸 Washington, D.C., District of Columbia, United States

University of Arkansas Winthrop P. Rockefeller Cancer Institute; 🇺🇸 Little Rock, Arkansas, United States

Medical University of South Carolina; 🇺🇸 Charleston, South Carolina, United States

Cedars-Sinai Medical Center; 🇺🇸 Los Angeles, California, United States

Northwestern University Robert H. Lurie Comprehensive Cancer Center; 🇺🇸 Chicago, Illinois, United States